In the MM-03 trial, G-CSF was used in 47% of patients, with low incidences of febrile neutropenia and most grade 3–4 infections being unrelated to neutropenia [22,32]; pomalidomide dosage was reduced in 27% of patients, and interrupted in 67% of cases for adverse events and low compliance [32]. The gene discussed is CSF3; the disease is infection.